" rel="stylesheet">
Skip Main Navigation
Page Content
This event has ended

Supreme Court Myriad decision: a panel discussion


Monday, July 1, 2013 from 6:00 PM to 8:00 PM (EDT)

Supreme Court Myriad decision: a panel discussion

Ticket Information

Donation Type Remaining Sales End Amount
General 5 Tickets Ended
Student/postdoc 2 Tickets Ended

Who's Going

Loading your connections...

Share Supreme Court Myriad decision: a panel discussion

Event Details

The recent Supreme Court Myriad decision in which genomic DNA was ruled ineligible to patent marks a great change in the IP of biotech and directly affects many companies.

Through a panel discussion, we hope to 1) generate some clarity for those navigating the waters of new decisions; and 2) come to some conclusion as to how companies and organizations should best respond to this significant change.
Panel speakers include John Murray of Tannenbaum, Helpern, Syracuse & Hirschtritt, Hans Saur of Bio (the national trade organization), Joseph Robinson of Troutman Sanders, Mitchell Wong of the Exeter Law Group, Laura Coruzzi of Jones Day and Kristin Neuman of MPEG LA.

This intimate event is geared towards those who need this IP knowledge including CEOs, TT people, patent people, etc. 
Please forward the invitation to those who should come. Space is very limited. 

Our thanks to Tannenbaum, Helpern, Syracuse and Hirschtritt for hosting the event.

Your choice of how much you want to donate. All proceeds go to events and none to us.


Panel speakers include 
1. John Murray of THSH 
John is originally from Bangor, Northern Ireland. He received his Ph.D. under the supervision of Professor Sir Alec J. Jeffreys from the University of Leicester, England. Prior to achieving his Ph.D. he studied genetics at the University of Edinburgh, Scotland. His Ph.D. thesis concerned the study of recombination mechanisms in human minisatellite DNA.
After receiving his Ph.D., John became a Post-Doctoral Fellow in New York under the supervision of Dr. Larry Shapiro at Mt. Sinai School of Medicine and later Columbia University. His post-doctoral work studied the structure of calcium-dependent cell adhesion molecules through the use of x-ray crystallography. John's practice focuses on complex life sciences litigation, prosecution and opinion work. He has particular experience in Hatch-Waxman litigation, biotechnology and medical device prosecution and generic pharmaceuticals opinion work. 
2. Hans Saur of Bio, Joseph Robinson of Troutman Sanders
Hans Sauer is Associate General Counsel for Intellectual Property for the Biotechnology Industry Organization (BIO), a major trade association representing over 1,100 biotechnology companies from the medical, agricultural, environmental, and industrial sector. At BIO, Mr. Sauer advises the organization's board of directors, amicus committee, and various staff committees on patent and other intellectual property-related matters. Prior to his current position, Mr. Sauer was Chief Patent Counsel for MGI Pharma, Inc., and Senior Patent Counsel for Guilford Pharmaceuticals Inc. Mr. Sauer has 13 years of professional in-house experience in the biotechnology industry, where he worked on several research and drug development programs, being responsible for patent prosecution and portfolio oversight, clinical trial health information privacy, and sales and marketing legal compliance. Mr. Sauer has an M.S. degree in Biology from the University of Ulm in his native Germany, a Ph.D. in Neuroscience from the University of Lund, Sweden, and a J.D. from Georgetown University Law Center in Washington, D.C.


3. Mitchell Wong of the Exeter Law Group
Mitchell M. Wong is one of only several American litigators qualified to practice across three continents: he is admitted in New York, England and Wales, and Hong Kong. In addition, he is a licensed patent practitioner in both the United States and Canada. Mr. Wong’s practice focuses on complex commercial disputes and intellectual-property litigation.
Mr. Wong has been responsible for numerous proceedings, including patent matters in both the federal courts and before the U.S. Patent & Trademark Office (in both inter partes and ex parte proceedings). In 2008, the New York State Legislature called Mr. Wong to testify as an impartial witness on the role of pharmaceutical patents in the commercialization of generic drugs. He has been appointed a Special Master for civil cases before the New York State Supreme Court

4. Laura Coruzzi of Jones Day
Dr. Laura Coruzzi has represented clients in biotechnology and pharmaceuticals for close to 30 years. Prior to joining Jones Day, she practiced at Pennie & Edmonds LLP and was one of the first members of that firm's biotechnology group founded by S. Leslie Misrock, affectionately known as the "father of biotechnology patent law." Laura's practice has evolved with the patent laws and matured with the needs of the biotechnology and pharmaceutical industries. Her practice involves all aspects of patent law as it relates to a variety of disciplines in the life sciences, including genetic engineering, molecular biology, virology, vaccines, immunology, therapeutic antibodies, biologic and small molecule therapeutics, diagnostics, drug discovery, and drug delivery.
5. Kristin Neuman of MPEG LA.
Kristin Neuman is the Executive Director of Librassay, a web-based patent licensing facility for diagnostics, biomarkers and related research tools in support of the new age of personalized medicine. Librassay® is sponsored by MPEG LA, the world's leader in patent pools and other one-stop IP licensing solutions.

Prior to joining MPEG LA in February of this year, Kristin was a senior intellectual property lawyer with Proskauer Rose, a large global law firm headquartered in New York City. Her practice focused on patent procurement, IP litigation, licensing and other business transactions in the fields of molecular diagnostics, biotechnology, pharmaceuticals and medical devices.

Kristin frequently writes and lectures on topics relating to patent law and the intersection of intellectual property, business and entrepreneurism.

Kristin holds a Bachelor of Arts in Biochemistry, Phi Beta Kappa, from the University of Colorado and a Juris Doctor from the Georgetown University Law Center. Prior to entering private practice, she clerked for the Honorable Roger B. Andewelt of the U.S. Court of Federal Claims in Washington, D.C.

She is also a board member of NYC Bio 

Have questions about Supreme Court Myriad decision: a panel discussion? Contact NYC Bio

When & Where

Tannenbaum, Helpern, Syracuse and Hirschtritt
900 Third Avenue,
12th floor
New York, NY 10022

Monday, July 1, 2013 from 6:00 PM to 8:00 PM (EDT)

  Add to my calendar
Supreme Court Myriad decision: a panel discussion
New York, NY Events Business

Please log in or sign up

In order to purchase these tickets in installments, you'll need an Eventbrite account. Log in or sign up for a free account to continue.